Pinned Tweet

ALT Our posts are intended for healthcare providers in the United States only. By following, you confirm that you are a US HCP. Please be welcoming and respectful of others. Derogatory posts or comments will be removed and future access to this page may be restricted. Due to the nature of our industry, we will remove comments that include medical advice or specific treatments. For any requests for medical information or to report adverse events or product complaints, please visit https://legendbiotech.com/contact-us/. If you prefer, you may report side effects to the US Food and Drug Administration (FDA) directly by visiting www.FDA.gov/medwatch or calling 1-800-FDA-1088
馃摙 Grant applications are now open for the ELITE Program!
Dedicated to fostering the next generation of scientific leaders in cellular therapy, ELITE recognizes and supports early- career researchers advancing innovation and impactful research. Guided by an independent Steering Committee of renowned experts.
Apply today.
Visit the website to learn more:
bit.ly/4vuXS5i
#ELITEProgram
#CellularTherapy
#ResearchInnovation
An estimated 36,000 new cases of multiple myeloma are projected in the U.S. in 2026. At Legend, we鈥檙e advancing cell therapy innovation to help expand access and improve outcomes, with the goal of transforming the future of care for patients.
Learn more about how Legend is advancing research in Multiple Myeloma: bit.ly/3PDdJzr
#MultipleMyeloma #mmsm
#CellTherapy #Innovation
#CART
Legend Biotech Medical Affairs retweeted
Applications are now open for Legend Biotech鈥檚 inaugural ELITE Program (Emerging Leadership & Innovation in Cell Therapy Excellence).
The annual grant initiative is designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma.
Through the ELITE Program, we鈥檙e investing in the next generation of innovators and the ideas that can help advance research, education, and care for patients living with multiple myeloma.
Applications are open through November 20, 2026. Learn more and apply: bit.ly/4wnt47v
Thank you for joining us at #IMS2026
Follow along for more updates
At #IMS2026, Dr. Binod Dhakal @bhemato will present real-world outcomes with BCMA-directed CAR-T therapy in earlier-line multiple myeloma.
#mmsm #CART #MultipleMyeloma
At #IMS2026, Dr. Adam Cohen @CohenAd_MMdoc will present long-term remission and survival outcomes from CARTITUDE-2 Cohort A evaluating BCMA-directed CAR-T therapy in multiple myeloma. Stay tuned for more.
#MultipleMyeloma #CART #mmsm
New data is coming to #IMS2026. Legend will share 5-year follow-up data from CARTITUDE-2 Cohort A.
Explore the details at the link below.
bit.ly/4ihwMLU
Join us at #IMS2026, where Dr. Hermann Einsele will present the first results from a prospective postauthorization safety study of a BCMA-directed CAR-T therapy in relapsed/refractory multiple myeloma. Stay tuned for updates from the meeting.
#MultipleMyeloma #CART #mmsm
Legend Biotech is excited to be in Scotland this week for IMS! Join us as we share new data, connect with the scientific community, and participate in discussions shaping the future of patient care. Stay tuned for updates from the meeting.
#IMS2026 #mmsm #celltherapy
Grant applications for the ELITE Program are now open!
Supporting early-career innovators in cellular therapy through collaboration, scientific excellence, and impactful research.
馃搮 Deadline: November 20, 2026
Visit the website to learn more: bit.ly/4vuXS5i
Legend Biotech will be in Scotland next week for #IMS2026! For the latest update on our science: bit.ly/4ihwMLU
#mmsm #CART
Complete your Friday evening with dessert at #SOHO and hear from Dr. Krina Patel as she discusses lessons from the CARTITUDE program and real-world evidence.
At #IMS2026, Legend Biotech will share updated long-term and real-world evidence from its CAR-T clinical program.
Click the link below to learn more: bit.ly/4ihwMLU
Legend Biotech Medical Affairs retweeted
New data is coming at #IMS26.
At the 23rd International @Myeloma_Society Annual Meeting in Glasgow, Legend Biotech will present data from our CAR-T cell therapy, including long-term, post-authorization and real-world findings.
These insights build on learnings from our clinical program as we continue our focus on advancing scientific innovation and reaching patients globally.
Learn more about the data we鈥檒l be sharing in Glasgow: bit.ly/4xITIZj
#LegendBiotech #CellTherapy #ClinicalResearch
At #SOHO2026, Dr. Roberto Mina (@RobertoMinaMD) of Emory University will present data from cytogenetic subgroup analysis examining bridging therapy in CARTITUDE-4.
#CART #mmsm
Legend Biotech is in Houston, Texas for #SOHO2026! Follow us scientific updates.
#mmsm #multiplemyeloma
The ELITE Program, sponsored by Legend Biotech, will support the next generation of scientific leaders in cellular therapy among US healthcare professionals.
Learn more: bit.ly/4vuXS5i
#ELITEProgram #CellTherapy #ScientificLeadership
Next week, Legend Biotech will be at #SOHO2026. Follow us scientific updates.
#mmsm #multiplemyeloma


















